Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

A Phase 2 clinical trial investigating the inhaled sarcoidosis therapy aviptadil — also known as RLF-100, and designed to block inflammation in the lungs — has been cleared to start in Germany.

The clearance by the German medical regulatory authority Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) was given to AdVita Lifescience, the original developer of aviptadil, which was recently acquired by Relief Therapeutics.

“Receiving regulatory clearance to begin a phase 2 clinical trial of inhaled aviptadil marks another clinical milestone for Relief and our subsidiary, AdVita,” Raghuram Selvaraju, chairman of the board of Relief, said in a press release.

https://sarcoidosisnews.com/2021/09/10/phase-2-trial-inhaled-sarcoidosis-therapy-aviptadil-cleared-germany/